Efficacy of a mitochondrion-targeting agent for reducing the level of urinary protein in rats with puromycin aminonucleoside-induced minimal-change nephrotic syndrome

PLoS One. 2020 Jan 6;15(1):e0227414. doi: 10.1371/journal.pone.0227414. eCollection 2020.

Abstract

Background: Oxidative stress is a major factor responsible for minimal-change nephrotic syndrome (MCNS), which occurs most commonly in children. However, the influence of oxidative stress localized to mitochondria remains unclear. We examined the effect of a mitochondrion-targeting antioxidant, MitoTEMPO, in rats with puromycin aminonucleoside (PAN)-induced MCNS to clarify the degree to which mitochondrial oxidative stress affects MCNS.

Materials and methods: Thirty Wistar rats were divided into three groups: normal saline group (n = 7), PAN group (n = 12), and PAN + MitoTEMPO group (n = 11). Rats in the PAN and PAN + MitoTEMPO groups received PAN on day 1, and those in the PAN + MitoTEMPO group received MitoTEMPO on days 0 to 9. Whole-day urine samples were collected on days 3 and 9, and samples of glomeruli and blood were taken for measurement of lipid peroxidation products. We also estimated the mitochondrial damage score in podocytes in all 3 groups using electron microscopy.

Results: Urinary protein excretion on day 9 and the levels of lipid peroxidation products in urine, glomeruli, and blood were significantly lower in the PAN + MitoTEMPO group than in the PAN group (p = 0.0019, p = 0.011, p = 0.039, p = 0.030). The mitochondrial damage score in podocytes was significantly lower in the PAN + MitoTEMPO group than in the PAN group (p <0.0001).

Conclusions: This mitochondrion-targeting agent was shown to reduce oxidative stress and mitochondrial damage in a MCNS model. A radical scavenger targeting mitochondria could be a promising drug for treatment of MCNS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Drug Delivery Systems*
  • Lipid Peroxidation / drug effects
  • Male
  • Mitochondria* / metabolism
  • Mitochondria* / pathology
  • Nephrosis, Lipoid* / chemically induced
  • Nephrosis, Lipoid* / drug therapy
  • Nephrosis, Lipoid* / pathology
  • Nephrosis, Lipoid* / urine
  • Organophosphorus Compounds / pharmacology*
  • Oxidative Stress / drug effects
  • Piperidines / pharmacology*
  • Podocytes / metabolism
  • Podocytes / pathology
  • Proteinuria* / chemically induced
  • Proteinuria* / drug therapy
  • Proteinuria* / pathology
  • Proteinuria* / urine
  • Puromycin Aminonucleoside / adverse effects*
  • Puromycin Aminonucleoside / pharmacology
  • Rats
  • Rats, Wistar

Substances

  • Antioxidants
  • MitoTEMPO
  • Organophosphorus Compounds
  • Piperidines
  • Puromycin Aminonucleoside

Grants and funding

This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP17K10161. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.